NIP
BHVN

Nicholas Investment Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Nicholas Investment Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-137,306
Closed -$20M – 208
2022
Q2 		$20M Sell
137,306
-38,977
-22% -$4.98M 1.89% 4
2022
Q1 		$20.9M Sell
176,283
-50,588
-22% -$6.31M 1.49% 16
2021
Q4 		$31.3M Buy
226,871
+24,966
+12% +$3.17M 1.98% 4
2021
Q3 		$28M Sell
201,905
-161,803
-44% -$20.2M 2.05% 2
2021
Q2 		$35.3M Sell
363,708
-11,946
-3% -$970K 2.21% 1
2021
Q1 		$25.7M Buy
375,654
+105,292
+39% +$8.52M 1.79% 4
2020
Q4 		$23.2M Buy
270,362
+18,416
+7% +$1.56M 1.79% 9
2020
Q3 		$16.4M Buy
251,946
+192,988
+327% +$12.6M 1.77% 12
2020
Q2 		$4.31M Sell
58,958
-101,553
-63% -$5.4M 0.87% 27
2020
Q1 		$5.46M Buy
160,511
+16,794
+12% +$768K 1.06% 21
2019
Q4 		$7.82M Sell
143,717
-20,202
-12% -$1M 0.81% 20
2019
Q3 		$6.84M Buy
163,919
+1,361
+0.8% +$57.5K 0.58% 51
2019
Q2 		$7.12M Buy
162,558
+54,516
+50% +$3.07M 0.65% 45
2019
Q1 		$5.56M Buy
108,042
+4,432
+4% +$191K 0.5% 54
2018
Q4 		$3.83M Buy
103,610
+16,596
+19% +$598K 0.41% 87
2018
Q3 		$3.27M Sell
87,014
-532
-0.6% -$19.6K 0.26% 151
2018
Q2 		$3.46M Sell
87,546
-693
-0.8% -$22K 0.24% 136
2018
Q1 		$2.27M Buy
+88,239
New +$2.64M 0.16% 182
2017
Q4 		– Sell
-96,367
Closed -$3.6M – 291
2017
Q3 		$3.6M Buy
96,367
+149
+0.2% +$4.52K 0.25% 133
2017
Q2 		$2.41M Buy
+96,218
New +$2.22M 0.17% 194

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nicholas Investment Partners's BHVN Position: Q3 2022 in Review

Nicholas Investment Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 137,306 shares — an estimated $20M sold.

Nicholas Investment Partners first reported a position in BHVN in Q2 2017 and held it in 20 quarters. The position peaked at $35.3M in Q2 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Nicholas Investment Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Nicholas Investment Partners sold 137,306 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $20M.
  • Nicholas Investment Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 20 quarters.
  • Nicholas Investment Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $35.3M in Q2 2021.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Nicholas Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.